NASDAQ:IBRX

ImmunityBio Competitors

$15.22

+0.76 (+5.26 %)

(As of 05/14/2021 12:19 PM ET)

Add

Compare

Today's Range

$14.28

▼

$15.40

50-Day Range

$15.19

▼

$30.89

52-Week Range

$4.15

▼

$45.42

Volume19,063 shs

Average Volume1.43 million shs

Market Capitalization$1.66 billion

P/E RatioN/A

Dividend YieldN/A

BetaN/A

ImmunityBio (NASDAQ:IBRX) Vs. ABCM, SANA, RXRX, NUVB, IMCR, and SEER

Should you be buying IBRX stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to ImmunityBio, including Abcam (ABCM), Sana Biotechnology (SANA), Recursion Pharmaceuticals (RXRX), Nuvation Bio (NUVB), Immunocore (IMCR), and Seer (SEER).

ImmunityBio vs. Abcam Stock

ImmunityBio (NASDAQ:IBRX) and Abcam (NASDAQ:ABCM) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation and analyst recommendations.

Profitability

This table compares ImmunityBio and Abcam's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ImmunityBio	N/A	N/A	N/A
Abcam	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of recent ratings and target prices for ImmunityBio and Abcam, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmunityBio	0	0	1	0	3.00
Abcam	0	4	3	0	2.43

ImmunityBio presently has a consensus target price of $25.00, suggesting a potential upside of 64.26%. Abcam has a consensus target price of $22.00, suggesting a potential upside of 10.11%. Given ImmunityBio's stronger consensus rating and higher probable upside, equities analysts clearly believe ImmunityBio is more favorable than Abcam.

Valuation & Earnings

This table compares ImmunityBio and Abcam's gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmunityBio	N/A	N/A	N/A	N/A	N/A
Abcam	N/A	N/A	N/A	N/A	N/A

Summary

ImmunityBio beats Abcam on 2 of the 3 factors compared between the two stocks.

ImmunityBio vs. Sana Biotechnology Stock

Sana Biotechnology (NASDAQ:SANA) and ImmunityBio (NASDAQ:IBRX) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, valuation, analyst recommendations, risk and institutional ownership.

Profitability

This table compares Sana Biotechnology and ImmunityBio's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sana Biotechnology	N/A	N/A	N/A
ImmunityBio	N/A	N/A	N/A

Valuation and Earnings

This table compares Sana Biotechnology and ImmunityBio's top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sana Biotechnology	N/A	N/A	N/A	N/A	N/A
ImmunityBio	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

This is a summary of current recommendations and price targets for Sana Biotechnology and ImmunityBio, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sana Biotechnology	0	2	2	0	2.50
ImmunityBio	0	0	1	0	3.00

Sana Biotechnology currently has a consensus target price of $40.00, suggesting a potential upside of 100.80%. ImmunityBio has a consensus target price of $25.00, suggesting a potential upside of 64.26%. Given Sana Biotechnology's higher probable upside, research analysts clearly believe Sana Biotechnology is more favorable than ImmunityBio.

Summary

Sana Biotechnology beats ImmunityBio on 2 of the 3 factors compared between the two stocks.

ImmunityBio vs. Recursion Pharmaceuticals Stock

Recursion Pharmaceuticals (NASDAQ:RXRX) and ImmunityBio (NASDAQ:IBRX) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, dividends, earnings, valuation and risk.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Recursion Pharmaceuticals and ImmunityBio, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Recursion Pharmaceuticals	0	2	3	0	2.60
ImmunityBio	0	0	1	0	3.00

Recursion Pharmaceuticals currently has a consensus price target of $33.20, indicating a potential upside of 52.08%. ImmunityBio has a consensus price target of $25.00, indicating a potential upside of 64.26%. Given ImmunityBio's stronger consensus rating and higher possible upside, analysts plainly believe ImmunityBio is more favorable than Recursion Pharmaceuticals.

Valuation & Earnings

This table compares Recursion Pharmaceuticals and ImmunityBio's revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Recursion Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ImmunityBio	N/A	N/A	N/A	N/A	N/A

Profitability

This table compares Recursion Pharmaceuticals and ImmunityBio's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Recursion Pharmaceuticals	N/A	N/A	N/A
ImmunityBio	N/A	N/A	N/A

Summary

ImmunityBio beats Recursion Pharmaceuticals on 2 of the 3 factors compared between the two stocks.

ImmunityBio vs. Nuvation Bio Stock

ImmunityBio (NASDAQ:IBRX) and Nuvation Bio (NYSE:NUVB) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, institutional ownership, dividends and analyst recommendations.

Analyst Ratings

This is a summary of current ratings for ImmunityBio and Nuvation Bio, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmunityBio	0	0	1	0	3.00
Nuvation Bio	0	0	6	0	3.00

ImmunityBio currently has a consensus price target of $25.00, indicating a potential upside of 64.26%. Nuvation Bio has a consensus price target of $17.40, indicating a potential upside of 56.33%. Given ImmunityBio's higher probable upside, research analysts plainly believe ImmunityBio is more favorable than Nuvation Bio.

Profitability

This table compares ImmunityBio and Nuvation Bio's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ImmunityBio	N/A	N/A	N/A
Nuvation Bio	N/A	N/A	N/A

Earnings and Valuation

This table compares ImmunityBio and Nuvation Bio's gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmunityBio	N/A	N/A	N/A	N/A	N/A
Nuvation Bio	N/A	N/A	N/A	N/A	N/A

ImmunityBio vs. Immunocore Stock

Immunocore (NASDAQ:IMCR) and ImmunityBio (NASDAQ:IBRX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, analyst recommendations, risk, valuation, dividends and institutional ownership.

Profitability

This table compares Immunocore and ImmunityBio's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Immunocore	N/A	N/A	N/A
ImmunityBio	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of recent recommendations for Immunocore and ImmunityBio, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunocore	0	1	2	0	2.67
ImmunityBio	0	0	1	0	3.00

Immunocore currently has a consensus target price of $54.3333, indicating a potential upside of 32.52%. ImmunityBio has a consensus target price of $25.00, indicating a potential upside of 64.26%. Given ImmunityBio's stronger consensus rating and higher probable upside, analysts clearly believe ImmunityBio is more favorable than Immunocore.

Earnings & Valuation

This table compares Immunocore and ImmunityBio's top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunocore	N/A	N/A	N/A	N/A	N/A
ImmunityBio	N/A	N/A	N/A	N/A	N/A

Summary

ImmunityBio beats Immunocore on 2 of the 3 factors compared between the two stocks.

ImmunityBio vs. Seer Stock

Seer (NASDAQ:SEER) and ImmunityBio (NASDAQ:IBRX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, dividends, risk, profitability and valuation.

Valuation & Earnings

This table compares Seer and ImmunityBio's revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Seer	N/A	N/A	N/A	N/A	N/A
ImmunityBio	N/A	N/A	N/A	N/A	N/A

Profitability

This table compares Seer and ImmunityBio's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Seer	N/A	N/A	N/A
ImmunityBio	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Seer and ImmunityBio, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seer	0	2	2	0	2.50
ImmunityBio	0	0	1	0	3.00

Seer currently has a consensus price target of $66.3333, suggesting a potential upside of 121.70%. ImmunityBio has a consensus price target of $25.00, suggesting a potential upside of 64.26%. Given Seer's higher possible upside, research analysts plainly believe Seer is more favorable than ImmunityBio.

Summary

Seer beats ImmunityBio on 2 of the 3 factors compared between the two stocks.